Alzheimer's Disease Clinical Trial
Official title:
A Prospective, Single Site, Single Arm, Non-randomized, Interventional Study to Evaluate the Safety and Effectiveness of Omental Transposition Surgery for Patients With Alzheimer's Disease.
This study is a prospective, single arm, non-randomized, interventional study to evaluate
the safety and effectiveness of Omental transposition (OT) in subjects with early stage AD.
Within-subjects (repeated-measures) design will be utilized to compare follow-up outcomes to
baseline.
The following assessments will be performed at baseline, then at 1, 3, 6, 12, and 24 months
following surgery:
- Montreal Cognitive Assessment (MoCA)
- Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog)
- General Practitioner Assessment of Cognition (GPCOG)
- Eight-item Informant Interview to Differentiate Aging and Dementia (AD8) Subjects who
have early stage AD confirmed by a neuropsychological test (MoCA) and who are healthy
enough to undergo surgery.
The experimental procedure to be performed is omental transposition (OT) surgery. It will be
performed as a laparoscopic or open procedure for omental lengthening and an open procedure
for brain access, with a general surgeon performing the omental lengthening/tunneling and a
neurosurgeon performing brain access/brain biopsy/omental placement on brain.
Up to twenty-five (25) subjects, with the first 5 subjects being part of a learning curve
group and the next 20 subjects being part of the experimental group.
The duration of each subject's participation will be approximately 25 months from screening
through the 24 month follow-up visit.
The experimental procedure to be performed is omental transposition surgery, during which a
general surgeon and a neurosurgeon work as a team to transpose a pedicle omental graft to
the surface of the brain. The general surgeon is responsible for performing a
laparotomy/laparoscopy, elongating the omentum into a long pedicle and developing an
extensive subcutaneous tunnel up the chest and neck to the head. The neurosurgeon is
responsible for performing the craniotomy and securing the omentum on the brain.
Creating an intact omental pedicled flap requires the services of a general surgeon and
neurosurgeon. The first step in the operation is to obtain access to the abdominal cavity
laparoscopically using four 5cm trocars, or via laparotomy through an upper midline
incision. The omentum is then removed from the transverse colon, after which it is separated
from its proximal and central attachments to the stomach. The omentum detachments are made
directly on the greater curvature of the stomach, leaving the gastroepiploic arteries and
veins within the still-connected omentum apron.
Final separation of the omentum from the proximal portion of the stomach is done by dividing
the left gastroepiploic vessels, which at the highest proximal level on the stomach become
the short gastric vessels. The vascular connections to and from the omentum are now
maintained solely from the right gastric and right gastroepiploic vessels. In order for the
omental pedicle graft to reach the brain without tension, further surgical tailoring of the
omentum is carried out, with care being taken to ensure the preservation of a major omental
artery and vein.
After the omentum has been lengthened to an appropriate extent to reach the head, several
small (3- to 4-inch) transverse incisions are made on the chest wall slightly lateral to the
midline, with the side of the midline to make the transverse incisions depending on which
cerebral hemisphere the omentum is to be placed. These transverse incisions are connected
subcutaneously, thus creating a tunnel that begins at the upper pole of the midline
abdominal incision and travels subcutaneously, up the chest wall and neck to behind the ear.
Although the subcutaneous tissue behind the ear is extremely dense, it is essential that the
tunnel at this location be at least 2-3 finger lengths in width so that there is no
constriction on the omentum in this particular area within the tunnel. As the omentum in the
tunnel passes behind the ear, it goes beneath the base of the scalp flap that had been
previously dissected in making the initial craniotomy incision.
The neurosurgery portion of the operation involves removal of a single piece of bone over
the temporal-frontal area, opening the dura mater, followed by the removal of patches of
arachnoid membrane, with care being taken to avoid blood vessels on the surface of the
brain.
At this point in the operation, the omentum is laid directly upon the
parietal-temporal-frontal area, after which the dura mater is sutured to the omentum. It is
not necessary that the edges of the omentum be applied to the cut edges of the dura since
the omentum can be tucked under the edges of the dura for greater coverage of the brain. The
edges of the dura are then sewn to the top surface of the omentum using absorbable sutures
and the craniotomy is closed.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02089555 -
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
|
N/A |